News Column

Medidata Reports Record Full Year and Fourth Quarter 2013 Results

February 6, 2014

Record full year revenue of $276.8 million , a 27% year-over-year increase Record full year subscription revenue of $227.9 million , a 33% year-over-year increase Raises 2014 revenue guidance to between $340 and $345 million NEW YORK --(BUSINESS WIRE)-- Medidata (NASDAQ:MDSO), the leading global provider of cloud-based solutions for clinical research in life sciences, today announced its financial results for the fourth quarter and full year 2013, and provided detailed financial guidance for the full year 2014. “Record revenues of $277 million in 2013 led to Medidata’s best year of growth since we went public in 2009. Subscription revenue growth of 33% was driven by accelerating customer adoption and market share gains,” said Tarek Sherif , Medidata's chairman and chief executive officer. “Our cloud platform is built on best-in-class technology supported by a deep understanding of clinical development, while our benchmarking and analytic capabilities are powered by the largest, unique data repository in our industry. This has made Medidata a key technology partner to the life sciences industry as we focus on optimizing value throughout the clinical development process. Given our healthy backlog, momentum and a great pipeline of opportunities, we are well positioned for another year of exciting growth.” Fourth Quarter 2013 Results Total revenue for the fourth quarter of 2013 was $74.6 million , an increase of $16.0 million , or 27%, compared with $58.6 million in 2012. Subscription revenue was $63.0 million , an increase of 32%, compared with the same period last year. GAAP operating (loss)* for the quarter was ($1.5) million , compared with income of $9.3 million in the fourth quarter of 2012. Non-GAAP operating income** for the fourth quarter of 2013 increased to $17.3 million , up 24%, compared with $14.0 million a year ago. For the fourth quarter and full year of 2013, GAAP results* include $9.3 million of additional stock-based compensation expense relating to long-term performance-based restricted stock units. GAAP net income* for the fourth quarter of 2013 was $0.6 million , or $0.01 per diluted share, compared with $6.6 million , or $0.13 per diluted share, in the fourth quarter of 2012. Adjusted non-GAAP net income** for the fourth quarter of 2013 was $12.5 million , or $0.23 per diluted share, up 37%, compared with $9.1 million , or $0.17 per diluted share, in the fourth quarter of 2012. See the non-GAAP reconciliation included in this release for full details of the non-GAAP adjustments. Cash flow from operations was $20.1 million in the fourth quarter, up $23.6 million compared with negative cash flow of ($3.5) million a year ago. Full Year 2013 Results Total revenue for the full year 2013 was $276.8 million , an increase of $58.5 million , or 27%, compared with $218.3 million in 2012. Subscription revenue was $227.9 million , an increase of 33% over 2012. GAAP operating income* for the full year 2013 was $23.9 million , compared with $27.9 million in 2012. Non-GAAP operating income** for the full year increased to $67.2 million , up 43%, compared with $47.1 million in 2012. GAAP net income* for the full year 2013 was $16.7 million , or $0.31 per diluted share, compared with $18.0 million , or $0.35 per diluted share, in 2012. Adjusted non-GAAP net income** for the full year 2013 was $41.8 million , or $0.77 per diluted share, up 58%, compared with $26.4 million , or $0.52 per diluted share, in 2012. See the non-GAAP reconciliation included in this release for full details of the non-GAAP adjustments. Total cash, cash equivalents and marketable securities were $436.3 million at the end of 2013, an increase of $313.7 million , or 256%, compared with $122.6 million at the end of 2012, primarily due to net proceeds of $279.4 million from the convertible senior notes issued during 2013 and record cash flows. Cash flow from operations was a record $69.6 million for the full year 2013, up 427% year over year. Additional Highlights Subscription backlog grew to a record $228 million, up 23% year over year. Subscription backlog does not include intra-year renewals. Medidata's revenue retention rate for the year was over 98%. The renewal rate for all its large enterprise customers over the last several years was 100%. 49% of customers had committed to multiple products at the end of 2013, up from 38% at the end of the previous year. Medidata's customer base grew to 397 in the fourth quarter of 2013, up 13% from the end of 2012. Non-Rave revenues increased 114% year-over-year, driven by adoption of Medidata’s innovative solutions for medical coding, randomization and trial supply management, safety data capture, and data-driven metrics and benchmarking. "Medidata delivered another strong year of accelerated revenue growth and margin expansion, while continuing to invest in corporate initiatives designed to drive sustainable growth," said Cory Douglas , chief financial officer. “Our fourth quarter and full year 2013 results demonstrate the cash flow potential, leverage and scalable nature of our vertically focused business model. Our revenue guidance for 2014 represents the highest growth rate we have provided at the start of a new year since our IPO." Financial Outlook For the full year 2014, the company now expects: Revenues between $340.0 and $345.0 million . Professional services revenues in the low-to-mid $50.0 million range. Non-GAAP operating income between $80.0 and $83.0 million . Based on current estimates, this would equate to GAAP operating income between $33.5 and $36.5 million . Adjusted non-GAAP net income, which includes the tax affected adjustments primarily from stock-based compensation, non-cash interest expense associated with convertible senior notes, and amortization at a 40% effective tax rate, between $41.0 and $44.0 million . Based on current estimates, this would equate to GAAP net income between $12.0 and $15.0 million . While changes in the stock price could change the fully diluted share count, the company is assuming 55.7 million fully diluted shares. Conference Call The company plans to host its investor conference call today at 8:00 a.m. Eastern. The investor conference call will be available via live webcast on the “Investor” section of Medidata’s web site at http://investor.mdsol.com . To participate by telephone, domestic participants may dial 877-303-2528 and international participants may dial 847-829-0023. Those interested in participating in the conference call should dial in at least 10 minutes prior to the call to register. Participants can also join the call via a simultaneous live audio webcast, which will be made available on the “Investor” section of Medidata’s web site at http://investor.mdsol.com . A replay of the conference call can be accessed until Thursday, February 20, 2014 , by dialing 800-585-8367 domestically or 404-537-3406 internationally, with the passcode 45357210. An archive of the call will also be hosted on the “Investor” section of Medidata’s web site, http://investor.mdsol.com , for a limited period of time. About Medidata Medidata is the leading global provider of cloud-based solutions for clinical research in life sciences, transforming clinical development through its advanced applications and intelligent data analytics. The Medidata Clinical Cloud™ brings new levels of productivity and quality to the clinical testing of promising medical treatments, from study design and planning through execution, management and reporting. We are committed to advancing the competitive and scientific goals of global customers, which include over 90% of the top 25 global pharmaceutical companies; innovative biotech, diagnostic and device firms; leading academic medical centers; and contract research organizations. Cautionary Statement Certain statements made in this press release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that involve significant risks and uncertainties about Medidata Solutions, Inc. (“Medidata”), including but not limited to statements about Medidata’s forecast of financial performance, products and services, business model, strategy and growth opportunities, and competitive position. Such statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in these statements. In particular, the risks and uncertainties include, among other things, risks associated with possible fluctuations in our financial and operating results; errors, interruptions or delays in our service or our Web hosting; the financial impact of any future acquisitions; our ability to continue to release, and gain customer acceptance of, new and improved versions of our products; changes in our sales and implementation cycles; competition; our ability to retain and expand our customer base or increase new business from those customers; our ability to hire, retain and motivate our employees and manage our growth; regulatory developments; litigation; and general developments in the economy. For additional disclosure regarding these and other risks faced by the company, see disclosures contained in Medidata’s public filings with the Securities and Exchange Commission including, the “Risk Factors” section of Medidata’s Annual Report on Form 10-K for the year ended December 31, 2012 . You should consider these factors in evaluating the forward-looking statements included in this press release and not place undue reliance on such statements. The forward-looking statements are made as of the date hereof, and Medidata undertakes no obligation to update such statements as a result of new information. *GAAP results include $9.3 million of stock-based compensation expense recognized during the fourth quarter of 2013 for the full year impact relating to long-term performance-based restricted stock units (units). These units contain performance targets measured on Medidata's three year compound annual revenue growth rate and total stockholder return. The recognition of expense for these units was based upon management’s assessment of the probability for achieving the predetermined performance targets and an estimate of the number of performance shares that will ultimately become earned on December 31, 2015 . The $9.3 million of stock-based compensation expense represents approximately one-third of the estimated current value of these awards. The remaining expense will be recognized ratably over 2014 and 2015. **Non-GAAP Financial Information Medidata provides non-GAAP operating income, net income and net income per share applicable to common stockholders data as additional information for its operating results. These measures are not in accordance with, or an alternative for, generally accepted accounting principles and may be different from non-GAAP measures used by other companies. Non-GAAP operating income excludes the impact of depreciation, amortization of intangible assets associated with acquisitions, stock-based compensation expense, and an adjustment to the fair value of contingent consideration. Non-GAAP net income excludes the impact of amortization of intangible assets associated with acquisitions, stock-based compensation expense, an adjustment to the fair value of contingent consideration, and non-cash interest expense on convertible senior notes. Adjusted non-GAAP net income excludes the impact of tax-affected amortization of intangible assets associated with acquisitions, stock-based compensation expense, an adjustment to the fair value of contingent consideration, and non-cash interest expense on convertible senior notes. Management uses these non-GAAP measures to evaluate its financial results, develop budgets, manage expenditures, and as an important factor in determining variable compensation. In addition, investors frequently have requested information from management regarding depreciation, amortization and other non-cash charges, such as share-based compensation, and management believes, based on discussions with investors, that these non-GAAP measures enhance investors’ ability to assess Medidata’s historical and projected future financial performance. While management believes these non-GAAP financial measures provide useful supplemental information to investors, there are limitations associated with the use of non-GAAP financial measures. One limitation of non-GAAP operating income is that it excludes depreciation and amortization, which represents the periodic costs of certain capitalized tangible and intangible assets used in generating revenues in our business. Medidata compensates for these limitations by using these non-GAAP financial measures as supplements to GAAP financial measures and by reviewing the reconciliations of the non-GAAP financial measures to their most comparable GAAP financial measures. Investors are encouraged to review the reconciliations of these non-GAAP financial measures to the comparable GAAP results, which are attached to this press release. MEDIDATA SOLUTIONS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except per share data) Three Months Ended December 31 , Twelve Months Ended December 31 , 2013 2012 2013 2012 Revenues (unaudited) Subscription (1) $ 62,977 $ 47,737 $ 227,921 $ 171,647 Professional services 11,598 10,893 48,928 46,700 Total revenues 74,575 58,630 276,849 218,347 Cost of revenues (2)(3) Subscription 9,735 8,501 37,053 32,600 Professional services 8,863 7,872 32,856 30,062 Total cost of revenues 18,598 16,373 69,909 62,662 Gross profit 55,977 42,257 206,940 155,685 Operating costs and expenses: Research and development (2) 14,062 10,454 51,202 42,276 Sales and marketing (2)(3) 20,150 12,946 66,337 47,739 General and administrative (2) 23,281 9,607 65,513 37,777 Total operating costs and expenses 57,493 33,007 183,052 127,792 Operating (loss) income (1,516 ) 9,250 23,888 27,893 Interest and other income (expense): Interest expense (3,747 ) (18 ) (5,925 ) (138 ) Interest income 311 84 555 280 Other (expense) income, net (54 ) 51 (136 ) 34 Total interest and other (expense) income, net (3,490 ) 117 (5,506 ) 176 (Loss) income before income taxes (5,006 ) 9,367 18,382 28,069 Provision for income taxes (5,588 ) 2,774 1,721 10,049 Net income $ 582 $ 6,593 $ 16,661 $ 18,020 Earnings per share: Basic (4) $ 0.01 $ 0.13 $ 0.33 $ 0.37 Diluted (4) $ 0.01 $ 0.13 $ 0.31 $ 0.35 Weighted average common shares outstanding: Basic (4) 51,685 49,960 51,060 49,092 Diluted (4) 54,825 51,896 54,118 50,938 (1) Subscription revenues, formerly known as application services revenues, represent subscription fees from customers accessing our enterprise cloud-based solutions, as well as other support services. (2) Stock-based compensation expense included in cost of revenues and operating costs and expenses is as follows: Cost of revenues $ 1,159 $ 459 $ 3,149 $ 1,751 Research and development 858 262 2,397 1,049 Sales and marketing 4,318 743 8,859 2,871 General and administrative 10,363 1,287 21,738 5,243 Total stock-based compensation (5) $ 16,698 $ 2,751 $ 36,143 $ 10,914 (3) Amortization expense of intangible assets included in costs of revenues and operating costs and expenses is as follows: Cost of revenues $ 105 $ 321 $ 589 $ 1,276 Sales and marketing 36 129 215 516 Total amortization of intangible assets $ 141 $ 450 $ 804 $ 1,792 (4) Prior period results have been adjusted to reflect the two-for-one stock split which was effected in the form of a stock dividend in December 2013 . (5) The three and twelve months ended December 31, 2013 include $9.3 million of expense associated with long-term performance based restricted stock units with a performance condition related to compound annual revenue growth and a market condition related to total stockholder return. For further information, refer to Reconciliation of GAAP Operating Income and GAAP Net Income to non-GAAP Operating Income, non-GAAP Net Income, and Adjusted non-GAAP Net Income. MEDIDATA SOLUTIONS, INC. Reconciliation of GAAP Operating Income and GAAP Net Income to Non-GAAP Operating Income, Non-GAAP Net Income, and Adjusted Non-GAAP Net Income (Unaudited) (Amounts in thousands, except per share data) Three Months Ended December 31 , Twelve Months Ended December 31 , 2013 2012 2013 2012 Operating (loss) income: GAAP operating (loss) income $ (1,516 ) $ 9,250 $ 23,888 $ 27,893 GAAP operating margins (2.0 )% 15.8 % 8.6 % 12.8 % Stock-based compensation (1) 16,698 2,751 36,143 10,914 Depreciation and amortization 2,048 1,937 6,936 7,934 Contingent consideration adjustment (2) 59 42 239 319 Non-GAAP operating income $ 17,289 $ 13,980 $ 67,206 $ 47,060 Non-GAAP operating margins 23.2 % 23.8 % 24.3 % 21.6 % Net income: GAAP net income $ 582 $ 6,593 $ 16,661 $ 18,020 Stock-based compensation (1) 16,698 2,751 36,143 10,914 Amortization 141 450 804 1,792 Contingent consideration adjustment (2) 59 42 239 319 Non-cash interest expense on convertible senior notes (3) 3,019 — 4,715 — Non-GAAP net income 20,499 9,836 58,562 31,045 Tax impact on add-back items (4) (7,966 ) (776 ) (16,760 ) (4,689 ) Adjusted non-GAAP net income $ 12,533 $ 9,060 $ 41,802 $ 26,356 GAAP basic earnings per share (5) $ 0.01 $ 0.13 $ 0.33 $ 0.37 GAAP diluted earnings per share (5) $ 0.01 $ 0.13 $ 0.31 $ 0.35 Non-GAAP basic earnings per share (5) $ 0.40 $ 0.20 $ 1.15 $ 0.63 Non-GAAP diluted earnings per share (5) $ 0.37 $ 0.19 $ 1.08 $ 0.61 Adjusted non-GAAP basic earnings per share (5) $ 0.24 $ 0.18 $ 0.82 $ 0.54 Adjusted non-GAAP diluted earnings per share (5) $ 0.23 $ 0.17 $ 0.77 $ 0.52 (1) Includes expense associated with long-term performance based restricted stock units with a performance condition related to compound annual revenue growth and a market condition related to total stockholder return, allocated to cost of revenues and operating costs and expenses as follows: Cost of revenues $ 379 $ — $ 379 $ — Research and development 361 — 361 — Sales and marketing 2,680 — 2,680 — General and administrative 5,905 — 5,905 — Total $ 9,325 $ — $ 9,325 $ — (2) Amount represents the effect of changes in fair value of contingent consideration liability. (3) During the third quarter of 2013, we issued $287.5 million in convertible senior notes (the "Notes") with a coupon interest rate of 1.00%. Interest is paid semiannually on February 1 and August 1 over the five-year term of the notes. In connection with the Notes, we are required to recognize non-cash interest expense, including amortization of debt discount and issuance costs, in accordance with accounting guidance for convertible debt that may be settled in cash. We exclude this incremental non-cash interest expense for purposes of calculating non-GAAP net income and adjusted non-GAAP net income. We believe that excluding these expenses from our non-GAAP measures is useful to investors because such incremental non-cash interest expense does not generate a cash outflow for the company and the debt issuance costs do not represent a cash outflow for the company except in the period the Notes were issued; therefore both are not indicative of our continuing operations or meaningful when comparing current results to past results. (4) Tax impact calculated using tax rates of 40% and 36% for 2013 and 2012, respectively. (5) Prior period results have been adjusted to reflect the two-for-one stock split which was effected in the form of a stock dividend in December 2013 . The table above presents a reconciliation of GAAP to non-GAAP operating (loss) income, net income, and net income per share applicable to common stockholders for the three and twelve months ended December 31, 2013 and 2012. Non-GAAP operating income excludes the impact of depreciation, amortization of intangible assets associated with acquisitions, stock-based compensation expense, and adjustment to the fair value of contingent consideration. Non-GAAP net income excludes the impact of amortization of intangible assets associated with acquisitions, stock-based compensation expense, adjustment to the fair value of contingent consideration, and non-cash interest expense on convertible senior notes. Adjusted non-GAAP net income excludes the impact of tax affected amortization of intangible assets associated with acquisitions, stock-based compensation expense, adjustment to the fair value of contingent consideration, and non-cash interest expense on convertible senior notes. MEDIDATA SOLUTIONS, INC. CONSOLIDATED BALANCE SHEETS (Amounts in thousands, except per share data) December 31, 2013 December 31, 2012 ASSETS Current assets: Cash and cash equivalents $ 22,328 $ 32,683 Marketable securities 218,892 89,871 Accounts receivable, net of allowance for doubtful accounts of $1,055 and $747 , respectively 45,534 42,359 Prepaid commission expense 3,615 2,281 Prepaid expenses and other current assets 13,511 8,042 Deferred income taxes 665 7,465 Total current assets 304,545 182,701 Restricted cash 5,118 388 Furniture, fixtures and equipment, net 41,229 10,474 Marketable securities, long-term 195,105 — Goodwill 15,487 15,382 Intangible assets, net 904 1,708 Deferred income taxes, long-term 345 11,055 Other assets 10,620 2,923 Total assets $ 573,353 $ 224,631 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable $ 7,524 $ 2,998 Accrued payroll and other compensation 27,773 14,140 Accrued expenses and other 12,265 6,729 Deferred revenue 52,628 50,348 Total current liabilities 100,190 74,215 Noncurrent liabilities: Convertible 1.00% senior notes, net 229,705 — Deferred revenue, less current portion 1,430 4,323 Deferred tax liabilities 5,651 624 Other long-term liabilities 10,564 3,378 Total noncurrent liabilities 247,350 8,325 Total liabilities 347,540 82,540 Commitments and contingencies Stockholders' equity: Preferred stock, par value $0.01 per share; 5,000 shares authorized, none issued and outstanding — — Common stock, par value $0.01 per share; 100,000 shares authorized, 55,018 and 52,810 shares issued; 53,634 and 52,078 shares outstanding, respectively (1) 550 528 Additional paid-in capital (1) 248,336 160,373 Treasury stock, 1,384 and 732 shares, respectively (26,414 ) (5,626 ) Accumulated other comprehensive loss (199 ) (63 ) Retained earnings (accumulated deficit) 3,540 (13,121 ) Total stockholders' equity 225,813 142,091 Total liabilities and stockholders' equity $ 573,353 $ 224,631 (1) Prior period results have been adjusted to reflect the two-for-one stock split which was effected in the form of a stock dividend in December 2013 . MEDIDATA SOLUTIONS, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS (Amounts in thousands) Year Ended December 31 , 2013 2012 Cash flows from operating activities: Net income $ 16,661 $ 18,020 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 6,936 7,934 Stock-based compensation 36,143 10,914 Amortization of discounts or premiums on marketable securities 3,075 1,573 Deferred income taxes (816 ) 3,123 Amortization of debt issuance costs 577 60 Amortization of debt discount 4,182 — Excess tax benefit associated with equity awards (4,531 ) (3,655 ) Contingent consideration adjustment 239 319 Provision for doubtful accounts 657 165 Loss on fixed asset disposal 241 — Changes in operating assets and liabilities: Accounts receivable 1,249 (16,056 ) Prepaid commission expense (535 ) (1,426 ) Prepaid expenses and other current assets 2,099 (2,553 ) Other assets (3,697 ) (1,372 ) Accounts payable (457 ) (823 ) Accrued payroll and other compensation 3,614 4,286 Accrued expenses and other 7,728 2,226 Deferred revenue (5,465 ) (11,471 ) Other long-term liabilities 1,697 1,981 Net cash provided by operating activities 69,597 13,245 Cash flows from investing activities: Purchase of furniture, fixtures and equipment (30,505 ) (5,742 ) Purchase of available-for-sale marketable securities (446,745 ) (109,320 ) Proceeds from sale of available-for-sale marketable securities 119,470 80,370 Net increase in restricted cash (4,956 ) — Net cash used in investing activities (362,736 ) (34,692 ) Cash flows from financing activities: Proceeds from exercise of stock options 10,452 9,328 Excess tax benefit associated with equity awards 4,531 3,655 Payment of acquisition-related earn-out (380 ) (251 ) Repayment of obligations under capital leases (75 ) (268 ) Proceeds from issuance of convertible senior notes 287,500 — Payment of costs associated with issuance of convertible senior notes (8,144 ) — Acquisition of treasury stock (10,828 ) (3,439 ) Repayment of notes payable (249 ) (113 ) Net cash provided by financing activities 282,807 8,912 Net decrease in cash and cash equivalents (10,332 ) (12,535 ) Effect of exchange rate changes on cash and cash equivalents (23 ) 4 Cash and cash equivalents - Beginning of period 32,683 45,214 Cash and cash equivalents - End of period $ 22,328 $ 32,683 Medidata Solutions Investor Contact: Hulus Alpay , 212-419-1025 halpay@mdsol.com or Media Contact: Gail Janowitz , 212-918-1792 gjanowitz@mdsol.com Source: Medidata


For more stories on investments and markets, please see HispanicBusiness' Finance Channel



Source: Business Wire


Story Tools